Transaction DateRecipientSharesTypePriceValue
17th September 2020Mark Anthony Mc Camish52,398Open or private purchase$5.83$305,249.79
16th September 2020Mark Anthony Mc Camish118,602Open or private purchase$5.73$679,968.99
2nd July 2020Jeffrey W Bird458,569Sale back to the issuer$18.00$8,254,242.00
2nd July 2020Jeffrey W Bird20,475Sale back to the issuer$18.00$368,550.00
2nd July 2020Jeffrey W Bird10,007Sale back to the issuer$18.00$180,126.00
2nd July 2020Jeffrey W Bird45,402Sale back to the issuer$18.00$817,236.00
23rd June 2020Ann D Rhoads4,000Open or private purchase$20.00$80,000.00
12th June 2020Jeffrey W Bird7,281Grant/award etc.$0.00
7th April 2020Ann D Rhoads37,414Sale back to the issuer$0.00
7th April 2020Jeffrey W Bird215,375Sale back to the issuer$0.00
Forty Seven
Forty Seven logo

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014.


Ticker: FTSV
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1667633
Employees: 57
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals